skip to Main Content

We are developing

Tomorrow’s immuno – modulators oncology therapy
A single platform for defeating cancer and much more.

We are HEPHAISTOS-Pharma

A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.

One need, one mission :

Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success level are still very low and only 10% of patients can be cured today.

Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients immune response and turning hidden cold tumors into hot targets for our immune system.

Team

International experts & experimented operational team

team-1

Chairwoman & CSO

Martine CAROFF
DSc., Inventor, Endotoxins biochemistry & Pertussis specialist. EU Woman Innovators Prize 2019.

team-2

Director & expert in Immunology

Jean-Marc CAVAILLON
DSc., Pr. Septic shock & innate immunity specialist. Former President of the International Endotoxin Society.

team-3

CEO & Business
Developer

Frederic CAROFF
MSc Centrale Paris, MBA Essec, Manager, Industrial scale up expert

team-4

CMC Manager

Alexey NOVIKOV
PhD, Head of Research Ability. Chemistry and Mass Spectrometry expert.

Jerome Kerzerho NB

Preclinical plan Manager

Jérôme KERZERHO
PhD, Immunologist, Immuno-oncology expert.

Advisory Board

team-6

Pr. Charles DUMONTET, MD PhD,

Lymphoma KOL
Deputy Director at Lyon Cancerology Research Center, Pr. of Hematology at the University of Lyon,

jean-yves-blay NB

Pr. Jean-Yves BLAY, MD PhD,

Sarcoma & GIST KOL
Director at Centre Léon BERARD, President of the European Organisation for Research and Treatment of Cancer,

team-5

Dr. Nathalie GARÇON, PharmD PhD,

Vaccine Immunostimulant KOL
CEO/CSO BIOASTER, 
Former GSK Vaccines Vice President,

Pierre Desmons

Dr. Pierre DESMONS, PhD

Pharma Manufacturing KOL
Owner at DESMONS Consulting,
Former GSK Vaccines Vice President

Market Needs

Turning cold tumors into hot tumors

Only 10% of patients are completely cured with immunotherapies
Clinicians need innovatives immuno-stimulators to turn cold tumors into hot tumors and improve the patients’ cure rate

Innovation & advantages

Onco-Boost platform

Natural TLR4
Immuno-stimulator

Detoxified LPS

Add-on Combination

with mAbs

Cure rate
10% ↑ 80%

Safer
Toxicity / 1000

Soluble
Easy formulation

Mechanism of Action

Mechanism of Action (MoA)

ONCO-Boost

will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.

Monoclonal
Antibody (mAb)

will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumor as a target to destroy.

All together

By recruiting and stimulating immune cells, ONCO-Boost enable treatment of tumors that were not previously sensitive to mAb’s action and open the way to treat incurable cancers.

Pipeline

Immuno Oncology

ONCO-Boost Immunotherapy

Human Vaccine

VAXI-Boost natural adjuvant

Clusters & Partners

supports

HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund

wilco

HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.

european-union

HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937

Sponsors CLARA

HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.

News

HEPHAISTOS-PHARMA presentation at BIOTUESDAYS

Frederic CAROFF presented the last updated results of…

Read more

HEPHAISTOS-Pharma laureate of i-Lab 2019

We are proud to announce that our project…

Read more

Martine CAROFF Laureate of the EU H2020 WIP2019

HEPHAISTOS-Pharma is proud to announce that our founder…

Read more

HEPHAISTOS-pharma laureate of H2020 SME Instrument

HEPHAISTOS-Pharma received a H2020 grant (SME Instrument Phase…

Read more

Contact

*

*

*

*

Back To Top